AFMD

Affimed N.V.

0.59 USD
+0.00 (+0.22%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Affimed N.V. stock is up 5.18% since 30 days ago. The next earnings date is Mar 21, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 60% of the previous 9 February’s closed higher than January.

About Affimed N.V.

Affimed N.V. focuses on discovering and developing cancer immunotherapies. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma. The company is also developing AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers.